A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 527-536

  Oh, Do Youn ^a   Cha, Yongjun ^a   Choi, In Sil ^b   Yoon, So Young ^c   Choi, In Keun ^d   Kim, Jee Hyun ^e   Oh, Sang Cheul ^d   Kim, Chang Duck ^d   Kim, Jae Sun ^d   Bang, Yung Jue ^a   Kim, Yeul Hong ^d  

^a Seoul National University   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Konkuk University Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Gemcitabine; Palliative; Pancreatic cancer; S 1

Indexed keywords

ANALGESIC AGENT; GEMCITABINE; PYRIMIDINE; S1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN INFARCTION; CANCER GROWTH; CANCER SURVIVAL; CEREBRAL VASCULAR INFARCTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OXONIC ACID; PANCREATIC NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 75549083878     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1059-9     Document Type: Article

References (29)

1. HR Shin YJ Won KW Jung, et al. 2005 Nationwide cancer incidence in Korea, 1999-2001; first result using the National Cancer Incidence Database Cancer Res Treat 37 325 331 10.4143/crt.2005.37.6.325 19956367
2. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
3. JD Berlin P Catalano JP Thomas JW Kugler DG Haller AB Benson 3rd 2002 Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 3270 3275 10.1200/JCO.2002.11.149 1:CAS:528:DC%2BD38XmsF2rs74%3D 12149301 (Pubitemid 34831525)
4. SR Bramhall J Schulz J Nemunaitis PD Brown M Baillet JA Buckels 2002 A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 161 167 10.1038/sj.bjc.6600446 1:CAS:528:DC%2BD38XltFeksLw%3D 12107836 (Pubitemid 34886337)
5. G Colucci F Giuliani V Gebbia, et al. 2002 Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 902 910 10.1002/cncr.10323 1:CAS:528:DC%2BD38XitVKhs74%3D 11920457 (Pubitemid 34150843)
6. H Oettle D Richards RK Ramanathan, et al. 2005 A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 1639 1645 10.1093/annonc/mdi309 1:STN:280:DC%2BD2MvpvFKhsg%3D%3D 16087696 (Pubitemid 41510138)
7. CM Rocha Lima MR Green R Rotche, et al. 2004 Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776 3783 10.1200/JCO.2004.12.082 1:CAS:528:DC%2BD2cXhtVCitb%2FO 15365074 (Pubitemid 41095218)
8. V Heinemann D Quietzsch F Gieseler, et al. 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946 3952 10.1200/JCO.2005.05.1490 1:CAS:528:DC%2BD28Xps1Sit78%3D 16921047 (Pubitemid 46630743)
9. C Louvet R Labianca P Hammel, et al. 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509 3516 10.1200/JCO.2005.06.023 1:CAS:528:DC%2BD2MXlsVyhsrg%3D 15908661 (Pubitemid 46243495)
10. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 10.1200/JCO.2006.07.9525 1:CAS:528: DC%2BD2sXmvVWmsr0%3D 17452677 (Pubitemid 46972777)
11. RA Miksad L Schnipper M Goldstein 2007 Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25 4506 4507 10.1200/JCO.2007.13.0401 17906218 (author reply 4508) (Pubitemid 350013866)
12. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212 2217 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D 17538165 (Pubitemid 46954645)
13. J Bernhard D Dietrich W Scheithauer, et al. 2008 Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001 J Clin Oncol 26 3695 3701 10.1200/JCO.2007.15.6240 1:CAS:528:DC%2BD1cXhtVGjs73N 18669454
14. Cunningham D, Chau I, Stocken D et al (2005) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 4:Abstract PSII
15. T Shirasaka Y Shimamato H Ohshimo, et al. 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 10.1097/00001813-199607000-00010 1:CAS:528:DyaK28Xltleru78%3D 8862723
16. T Takechi K Nakano J Uchida, et al. 1997 Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats Cancer Chemother Pharmacol 39 205 211 10.1007/s002800050561 1:CAS:528:DyaK2sXis1ajsL4%3D 8996521 (Pubitemid 26414256)
17. H Ueno T Okusaka M Ikeda Y Takezako C Morizane 2005 An early phase II study of S-1 in patients with metastatic pancreatic cancer Oncology 68 171 178 10.1159/000086771 1:CAS:528:DC%2BD2MXntFSnur8%3D 16006754 (Pubitemid 41158973)
18. T Okusaka A Funakoshi J Furuse, et al. 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621 10.1007/s00280-007-0514-8 1:CAS:528:DC%2BD1cXjsFWktw%3D%3D 17520253
19. CM Halloran P Ghaneh S Shore, et al. 2004 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells J Gene Med 6 514 525 10.1002/jgm.540 1:CAS:528:DC%2BD2cXlt1Cmsbg%3D 15133762 (Pubitemid 40228067)
20. H Ueno T Okusaka M Ikeda, et al. 2005 A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer Oncology 69 421 427 10.1159/000089997 1:CAS:528:DC%2BD2MXhtlWiurnO 16319514 (Pubitemid 41797919)
21. DL Longo PL Duffey VT DeVita Jr MN Wesley SM Hubbard RC Young 1991 The calculation of actual or received dose intensity: a comparison of published methods J Clin Oncol 9 2042 2051 1:STN:280:DyaK38%2FksVOhsg%3D%3D 1941063
22. Ueno H, Okusaka T, Furuse J et al (2007) A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. 25:Abstract No. 4550
23. Lee GW, Kim HJ, Ju JH et al (2009) Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol (in press)
24. K Nakamura T Yamaguchi T Ishihara, et al. 2005 Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 92 2134 2139 10.1038/sj.bjc.6602644 1:CAS:528:DC%2BD2MXltVygtbo%3D 15942632 (Pubitemid 40966247)
25. K Nakamura T Yamaguchi T Ishihara K Sudo H Kato H Saisho 2006 Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 94 1575 1579 1:CAS:528:DC%2BD28XltVOmurs%3D 16721372
26. MK Kim KH Lee BI Jang, et al. 2009 S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer Jpn J Clin Oncol 39 49 53 10.1093/jjco/hyn126 19060295
27. D Wong AH Ko J Hwang AP Venook EK Bergsland MA Tempero 2008 Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy Pancreas 37 269 274 10.1097/MPA.0b013e31816d8185 18815548
28. Y Murakami K Uemura T Sudo, et al. 2008 Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma Am J Surg 195 757 762 10.1016/j.amjsurg.2007.04.018 1:CAS:528:DC%2BD1cXmsFKqtrg%3D 18367131 (Pubitemid 351749450)
29. Murakami Y, Uemura K, Sudo T et al (2009) Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 13:85-92